Sun Pharmaceutical Industries Ltd - Stock Analysis by Finology

Every time a doctor writes a prescription in India, there is a good chance one of Sun Pharma’s brands is part of that treatment journey. From diabetes and heart care to skin, eye care, infections and pain management, the company manufactures and sells medicines across one of the widest portfolios in the country. Sun Pharma is India’s largest pharma company and has a presence in more than 100 countries. But does this scale, product depth and global reach make it a good investment today? Let us find out.

So, What Does Sun Pharma Actually Do?

Sun Pharma is a pharmaceutical company. In simple words, it manufactures and sells medicines. 

But its business is not limited to one type of medicine or one country. Sun Pharma sells medicines in India, the US, emerging markets and other developed markets. It operates in more than 100 countries and has 40 manufacturing facilities across six continents. 

The company mainly works in the formulations business. A formulation means the final medicine that a patient actually uses, like a tablet, capsule, injection, cream, syrup, ointment or eye drop. This is different from an API, which is only the core ingredient used to make the medicine.

In simple terms, API is the core ingredient, like paracetamol or ibuprofen. When paracetamol API is converted into tablets like Crocin, Calpol or Dolo, or ibuprofen API is converted into tablets like Brufen or Ibugesic, it becomes a formulation, meaning the final medicine used by patients.

Over the years, Sun Pharma has also moved beyond plain generic medicines. Its business now has three important pillars: India branded medicines, global generics and Innovative Medicines. The Innovative Medicines portfolio includes products such as ILUMYA (for moderate-to-severe plaque psoriasis), CEQUA (for dry eye disease), WINLEVI (for acne), ODOMZO (for advanced basal cell carcinoma, a type of skin cancer), LEQSELVI (for severe alopecia areata, an autoimmune hair-loss condition) and UNLOXCYT (for advanced cutaneous squamous cell carcinoma, another type of skin cancer).

(Source - Company)

Sun Pharma’s business can be understood in four parts.

1. India branded medicines business:
In India, Sun Pharma sells branded medicines that doctors prescribe to patients. These are mostly branded generic medicines, meaning off-patent medicines sold under Sun Pharma’s own brand names.

This business is driven by doctor trust, brand recall, medical representatives and distribution reach.

Sun Pharma is the largest pharma company in India, with around 8.4% market share as of Q4 FY26. It also has more than 15,000 medical representatives and is ranked No. 1 by prescriptions across 14 doctor categories.

Its India formulation sales stood at around ₹19,290 crore in FY26, contributing nearly 33% of total revenue.

2. US and global generics business:
In the US, Sun Pharma sells generic medicines. These are cheaper versions of medicines whose patents have expired.

This business is more competitive because many companies can sell the same molecule. So success depends on pricing, manufacturing quality, regulatory approvals and reliable supply.

The US business contributed around 29% of FY26 revenue, with sales of around $1.90 billion, down 0.9% YoY.

Sun Pharma is the 13th largest generic pharmaceutical company in the US. It also holds the 2nd position by prescriptions in the US dermatology market.

3. Specialty or innovative medicines business:
This is the higher-value part of Sun Pharma’s business.

Specialty medicines are differentiated products used in areas like dermatology, eye care and cancer-related treatments. Products such as Ilumya, Cequa, Winlevi, Odomzo, Leqselvi and Unloxcyt are part of this portfolio.

This business is important because it can offer better growth and stronger pricing power than plain generics.

In FY26, Sun Pharma’s Global Innovative Medicines revenue grew 16.8% to US$1.42 billion and contributed 22.2% of Sun Pharma’s total sales. This shows that Innovative Medicines are becoming a larger part of Sun’s overall business mix.

4. Emerging Markets, RoW and API Business
Apart from India and the US, Sun Pharma also sells medicines in emerging markets and other developed markets. This gives the company a more diversified revenue base and reduces dependence on only one geography.

In FY26, the revenue mix was broadly India 33%, US 29%, Emerging Markets 19%, Rest of World 15%, and API & Others around 4%.

The Emerging Markets business continued to grow well, supported by markets such as Romania, South Africa and Brazil. In FY26, Emerging Markets formulation revenue stood at US$1.26 billion, growing 13.6% YoY.

The Rest of World business also saw healthy growth. In FY26, RoW formulation revenue stood at US$969 million, growing 14.4% YoY. This business includes developed and other international markets outside India, the US and Emerging Markets.

The API business remains relatively small, contributing around 4% of FY26 revenue. This shows that Sun Pharma is mainly a formulation-led company, not an API-led company.

(Source - Company)

Now, Let's Look at the Financial Performance

Sun Pharma’s numbers have improved steadily over the last few years. The company’s revenue increased from around ₹33,498 crore in FY21 to around ₹58,462 crore in FY26, implying a CAGR of nearly 12%. During the same period, profit increased from around ₹2,272 crore to around ₹11,509 crore, implying a CAGR of nearly 38%.

(Source - Company, Finology Ticker)

The growth has also been broad-based. India formulations increased from ₹10,300 crore in FY21 to ₹16,923 crore in FY25. US formulations increased from ₹10,100 crore to ₹16,240 crore during the same period. Emerging Markets grew from ₹5,800 crore to ₹9,416 crore, while Rest of world (RoW) increased from ₹4,900 crore to ₹7,163 crore. So, Sun Pharma has not grown because of just one market. The growth has come across India, US, Emerging Markets and RoW.

(Source - Company)

What makes the numbers better is that profit has grown faster than sales. Sun Pharma’s gross margin improved from 73.1% in FY22 to 80.2% in FY26. EBITDA margin also improved from 27% to 30%. So, the margin improvement is not a one-quarter event. It has been building gradually as the business mix has improved.

A major reason for this is the rising contribution from specialty or innovative medicines. This business contributed only 7.3% of sales in FY18, but increased to 22.2% of sales in Q4 FY26. In absolute terms, innovative medicines sales increased from US$485 million in FY21 to US$1.42 billion in FY26, which means this business has become much larger within Sun Pharma’s overall mix. 

Since specialty medicines are more differentiated than plain generics, they generally support better margins and pricing power. Unbranded generics usually operate at much lower margins of around 4-12%, while branded generics can earn around 18-32%. Differentiated innovator or specialty medicines can be materially higher, with margins of around 35-55% once scaled.

R&D is another important part of the story. Sun Pharma has consistently spent around 5.5% to 6.7% of sales on R&D in recent years. In simple words, the company is continuously investing in future products, especially complex generics and specialty medicines, instead of only relying on its existing portfolio. Of the total R&D spend, 38.7% was for Innovative Medicines R&D.

In the US pipeline, Sun has filed 674 ANDAs, or Abbreviated New Drug Applications, and received 552 approvals, leaving around 122 pending. ANDA is mainly used to get approval for generic versions of already approved drugs. Sun has also filed 70 NDAs, or New Drug Applications, and received 57 approvals. NDA is used when a company seeks approval for a new drug or innovative medicine.

(Source - Company)

Return ratios have also improved. ROCE increased from 17% in FY22 to 21% in FY26. This is a good sign because Sun Pharma is investing in R&D, specialty products and acquisitions, but still improving capital efficiency.

One small concern is that borrowings increased during FY26. This was mainly because Sun Pharma took short-term borrowing for the Checkpoint acquisition, through which it added UNLOXCYT, an FDA-approved skin cancer treatment, to its Innovative Medicines portfolio. The company also had cash outflows related to the GxMDL settlement and other legacy settlements during the year. Management has indicated that this borrowing is short-term in nature and should reduce over time. Despite this, Sun Pharma continues to have a net cash balance sheet, with consolidated net cash of US$3.2 billion at the end of FY26.

Overall, Sun Pharma’s financial performance shows a clear shift. The company is growing across markets, margins are improving and specialty medicines are becoming a larger part of the business. The only area that needs close tracking is the US generics business, where competition and compliance issues continue to create pressure.

But Is the Pharma Market Still Big Enough for Sun Pharma to Grow?

The short answer is yes. The pharma market is still a large and growing opportunity, both in India and globally. But the growth is not the same across all parts of the business.

India’s pharma market is around US$60 billion today and is expected to reach nearly US$130 billion by 2030. India is already the 3rd largest pharma market by volume, but only 11th by value, which shows that medicine usage is high, but pricing is still much lower than developed markets.

This is important for Sun Pharma because India contributes around 33% of FY26 revenue. So, even if Sun only grows in line with the market, India can remain a steady growth engine. But if it continues gaining share through volumes, new launches and field-force expansion, growth can be better than the industry.

The US generics market is also large, but it is not as attractive as India from a pricing-power point of view. The US generic drugs market was estimated at around US$146 billion in 2025 and is expected to reach around US$244 billion by 2035, growing at a CAGR of around 5.25%.

For Sun Pharma, this means the US will remain a large market, but not an easy one. In ordinary generics, competition is high, buyers are powerful, and price erosion is common. FDA analysis shows that once generic competition enters, prices fall sharply. With the first generic competitor, prices can fall meaningfully, and with 6 or more competitors, generic prices can be more than 95% lower than the original branded drug price.

This is why Sun’s opportunity in the US is not just about selling more plain generics, but about focusing on complex generics, specialty products and differentiated medicines where competition is lower and pricing power is better.

Emerging markets also offer a steady opportunity. These markets are still underpenetrated compared to developed countries, and rising healthcare access can support long-term medicine demand. This gives the company a diversified base outside India and the US. Emerging pharma markets are expected to add around US$121 billion of pharmaceutical growth by 2030, which shows the scale of the opportunity.

So, the market opportunity is clearly not the problem. India offers steady branded-generic growth, the US offers scale but with pricing pressure, and specialty medicines offer the possibility of higher-quality growth.

What Can Drive Sun Pharma’s Growth From Here?

Sun Pharma’s next phase of growth is likely to come from four main areas: India branded medicines, Innovative Medicines, new launches such as semaglutide, and selective acquisitions.

In India, Sun Pharma already has a strong base. What makes this more interesting is that Sun pharma  is growing ahead of the market. In Q4 FY26, the company’s volume growth was 6%, while the broader Indian pharma market volume growth was only 1.6%. This means the Sun pharma  is not growing only because medicine prices are going up. It is also gaining through more prescriptions, higher volumes, new launches and stronger doctor connect.

The India business also benefits from its strong chronic therapy presence across cardiology, diabetes, neuropsychiatry, gastroenterology, dermatology and ophthalmology. Chronic therapies usually grow more steadily because patients need medicines for longer periods, while acute therapies like pain, infections or fever are more seasonal and episodic. Chronic therapies formed around 53% of India’s domestic formulation market in FY24 and are expected to rise to 55-57% by FY29. They are also expected to grow faster at 8.5-9.5% CAGR from FY24 to FY29, compared with 7-8% CAGR for acute therapies. This gives Sun’s chronic-heavy portfolio a useful long-term advantage.

A key growth area in India will be new product launches. Sun launched semaglutide injection under the brands Noveltreat and Sematrinity across both indications, chronic weight management and type 2 diabetes, and across all strengths. This is important because India has a very large addressable patient pool, with around 90 million adults living with diabetes and a large overweight/obese population as well. If Sun can gain doctor adoption and make the product affordable for patients, semaglutide can strengthen its diabetes and metabolic portfolio.

The bigger long-term shift is happening in Innovative Medicines. This business grew to US$1.42 billion in FY26 and contributed 22.2% of Sun Pharma’s Q4 FY26 sales. This is important because Innovative Medicines are more differentiated than plain generics and can give Sun better pricing power, stronger brand stickiness and a better growth profile over time.

ILUMYA remains the most important product in this portfolio. It is a biologic medicine used for the treatment of moderate-to-severe plaque psoriasis, a chronic skin condition where patients develop red, scaly and inflamed patches on the skin. It generated global sales of US$796 million in FY26, growing 16.7%. Sun is now trying to expand ILUMYA beyond psoriasis into psoriatic arthritis, a related condition where psoriasis patients also develop joint pain, stiffness and swelling. The US FDA has accepted the BLA review for this indication, with the regulatory action date set for late October 2026. If approved, this can open a larger patient base for ILUMYA and extend the product’s growth runway.

The US business is also changing in quality. Earlier, Sun’s US story was largely about generics, where competition and price erosion are common. But in FY26, management highlighted that US Innovative Medicines crossed US$1 billion for the first time and became larger than the US generics business. This is a major mix shift. It shows that Sun is slowly moving its US business away from plain generics toward more differentiated products.

Outside India and the US, Sun is also building scale in emerging markets and rest of world markets. This helps reduce dependence on one geography. Emerging markets offer long-term opportunity because healthcare access is still improving in many countries, and branded medicines can have better stickiness than commodity generics. Sun’s presence in more than 100 countries gives it a wide platform to launch and scale products across markets.

Acquisitions have also been an important part of Sun’s growth strategy. Deals such as Ranbaxy, ILUMYA, ODOMZO, CEQUA, WINLEVI, Concert Pharma and Checkpoint Therapeutics helped Sun expand its global platform and build its Specialty portfolio.

(Source - Company)

The proposed Organon acquisition, if completed, can become another large growth lever. Management said the combined company would have around US$12.4 billion revenue, which is roughly ₹1,18,000 crore at the current exchange rate. For context, Sun Pharma’s current revenue is around ₹58,462 crore, so the combined entity would be almost 2x its current size. The deal can also increase the innovative medicines share moving from 20% to 27%. It can also add stronger global commercial reach, especially in markets like Europe, China and South Korea, where Sun can potentially scale products like Ilumya, Leqselvi and Unloxcyt through a wider platform.

Between FY10 and FY25, Sun Pharma’s revenue grew from US$823 million to US$6.2 billion, while EBITDA increased from US$287 million to US$1.8 billion, implying a 14.4% revenue CAGR and 13% EBITDA CAGR. So, while deals like Ranbaxy were difficult initially, Sun pharma   has generally shown a good ability to integrate acquisitions and create value over time.

So, the real growth story is not just that Sun Pharma will sell more medicines. The bigger story is business mix improvement. The company is trying to protect its strong India base, reduce dependence on plain US generics, scale Innovative Medicines, enter newer therapy areas, and use acquisitions to expand global reach.

But What Can Go Wrong?

Sun Pharma is a strong business, but it is not without risks. The biggest risk is still the US business, especially the plain generics portfolio. In FY26, Sun pharma's US sales were around US$1.9 billion and recorded a marginal decline of 0.9% YoY. In Q4 FY26 also, US sales declined 1.1% YoY to US$459 million. Across the last few concalls, management repeatedly highlighted the same issue: growth in Innovative Medicines is getting partly offset by lower sales in generics due to additional competition in certain products and lower lenalidomide contribution. So, the concern is not that Sun is weak in the US, but that the older US generics business is still not showing a clean recovery.

The proposed Organon acquisition can also be a double-edged sword. If completed, it can increase the combined company’s revenue but it will also increase debt, with management indicating net debt to EBITDA of around 2.3x after the deal. So integration and deleveraging will be important.

Regulatory risk also remains an important monitorable. Sun Pharma has been dealing with USFDA compliance-related issues at facilities such as Halol, Mohali and Dadra. Halol remains a key concern because the facility has been under import alert, which can restrict shipments to the US, except for certain exemptions. More recently, the Baska facility was also classified as OAI, which means “Official Action Indicated”. In simple terms, the USFDA found issues serious enough to require official regulatory action or follow-up. If such issues take longer to resolve, new approvals can get delayed and the recovery in US generics can remain weak. This matters because Sun needs fresh launches and complex products to offset pricing pressure in older generic products. 

How Does Sun Pharma Compare With Other Pharma Companies?

We have compared Sun Pharma with Cipla, Dr. Reddy’s, Lupin because they are its closest large Indian pharma peers.

These companies operate across similar areas such as India formulations, US generics, complex products, chronic therapies and global markets.

Company	Mcap	EBITDA Margin	R&D Spend	India Exposure	US / North America Exposure	Key Takeaway
Sun Pharma	₹4,24,706 Cr.	30%	6.1% of revenue	33%	29%	Largest and most diversified, with India leadership, US scale and specialty portfolio
Cipla	₹1,10,822 Cr.	21%	~7% of revenue	45%	24%	Strong India plus US business, especially respiratory and complex products
Dr. Reddy’s	₹1,05,768 Cr.	19%	~7% of revenue	~19%	~34%	More US and global generics-heavy, with higher dependence on North America
Lupin	₹1,02,144 Cr.	32%	~8% of revenue	~31%	~44%	Strong US and India formulations player, with meaningful presence in complex generics, respiratory and chronic therapies.

Sun Pharma stands out because it has one of the most balanced business mixes in Indian pharma. India contributes around 33% of revenue and the US contributes around 29%, so the company is not overly dependent on one geography. It also has a broad therapy presence across cardiology, diabetes, gastro, neuropsychiatry, dermatology and ophthalmology, while its specialty business is focused on areas like dermatology, eye care and onco-dermatology.

Compared with peers, Cipla is more respiratory-led, while Dr. Reddy’s and Lupin have higher US exposure and are more dependent on generics and complex products. Sun sits in the middle with India leadership, US scale, specialty medicines, emerging markets and a strong balance sheet.

Valuation Analysis:

The earnings multiple approach is better suited for Sun Pharma because the company has a stable profit base, an established business model and reasonably predictable earnings.

A 12% EPS CAGR over the next 10 years looks reasonable for Sun Pharma, supported by its strong India business, growing specialty portfolio, and the Indian pharma market’s expected growth from US$60 billion to nearly US$130 billion by 2030.

An exit multiple of 28x P/E is broadly in line with Sun Pharma’s long-term median valuation. So, this approach does not assume any aggressive re-rating. The valuation is mainly driven by earnings growth, rather than expecting the market to assign a much higher multiple later.

A 12% discount rate and 20% margin of safety also make the valuation more disciplined, while giving some cushion against risks related to growth, margins, regulation and execution.

To calculate the fair value of a stock, you can use the EPS multiple technique on Finology Ticker.

Why have we rejected Sun Pharmaceutical Industries Ltd from Finology 30?

The US business remains a key monitorable because plain generics continue to face competition, buyer pressure and price erosion. 

Regulatory risk is another important factor. In the US pharma market, manufacturing compliance is critical because any delay in resolving plant-related issues can affect approvals and new launches.

Sun Pharma is buying Organon at an enterprise value of around US$11.75 billion, which can nearly double the combined revenue base to around US$12.4 billion. But the deal also brings around US$8.6 billion of Organon debt, taking post-deal net debt to EBITDA to around 2.3x.

That changes Sun’s investment case. It moves from being a net-cash pharma compounder to a larger, leveraged global pharma platform. Organon brings scale in women’s health, biosimilars and established brands, but a meaningful part of the portfolio is mature.

At this stage, we would prefer to wait for better clarity on Organon integration, debt reduction and whether the acquisition improves growth without diluting the quality of Sun’s existing business.

We are capturing the healthcare theme in Finology 30 through two different businesses with cleaner visibility.

One is a leading pharma player with a strong India franchise, meaningful North America exposure, healthy margins and a net cash balance sheet.

The other is a pharma company with strong brand recall, deep distribution reach and leadership across its core categories.